The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Travere Therapeutics Eyes Q4 Earnings Results Amid Significant Insider Selling

Travere Therapeutics (TVTX) is scheduled to release its fourth-quarter 2025 financial results on February 19 before the market opens. Market analysts are currently forecasting a loss of $0.05 per share for the quarter, reflecting the ongoing investment phase of the biotech firm. Despite the projected loss, the company maintains a "Moderate Buy" consensus rating with an average price target of $38.62. However, investor sentiment may be tempered by significant insider activity, as executives including CEO Eric M. Dube sold over $11 million in shares during the last quarter. This combination of optimistic analyst targets and heavy insider selling creates a complex outlook for the stock ahead of the announcement. Market participants will be closely watching for updates on the company's clinical pipeline and revenue growth during the earnings call to gauge future performance.